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We report dengue virus type 4 (DENV-4) in Amazonas, 
Brazil. This virus was isolated from serum samples of 3 
patients treated at a tropical medicine reference center in 
Manaus. All 3 cases were conﬁ  rmed by serologic and mo-
lecular tests; 1 patient was co-infected with DENV-3 and 
DENV-4.
D
engue fever is the main arthropod-borne viral disease 
of humans and a resurgent global public health con-
cern; an estimated 50–100 million cases occur every year, 
primarily in the tropical regions of the world (1–3). Den-
gue viruses (DENVs) belong to the genus Flavivirus, fam-
ily Flaviviridae. They are single-stranded, positive-sense, 
RNA viruses grouped into 4 antigenically related, but dis-
tinct, serotypes (DENV-1 to DENV-4) (1).
DENV infection has increased in Brazil in the past 
decade, particularly after 1994, as a result of Aedes ae-
gypti dissemination. Vector dispersion was followed by 
introduction of DENV-1, DENV-2, and DENV-3 in major 
Brazilian cities. Co-circulation of different serotypes has 
caused cases of the more severe forms of dengue, name-
ly, dengue hemorrhagic fever (DHF) and dengue shock 
syndrome (DSS) (4). Two dengue epidemics occurred in 
Manaus (3°5′S, 60°W), the capital of the state of Amazonas 
(Figure), during 1998–1999 and in 2001 (5,6). DHF cases 
were observed in association with DENV-1 and DENV-2 
in the most recent epidemic. Currently, DENV-3 also co-
circulates in Manaus (7).
The Study
A study on serologic and molecular characterization of 
DENV isolates was initiated in January 2005 at the Funda-
ção de Medicina Tropical do Amazonas (FMTAM). Para-
site-negative patients who had clinical symptoms of ma-
laria were invited to participate in the study. Each patient 
received essential information and signed a consent form 
approved by the FMTAM ethical committee. 
All serum samples were collected during the acute 
phase of illness and tested for DENV infection by using 
3 methods. The ﬁ  rst method was virus culture, for which 
serum samples were placed on the Aedes albopictus cell 
line C6/36 grown in Leibovitz-15 medium containing 5% 
fetal bovine serum, followed by viral antigen identiﬁ  cation 
with type-speciﬁ  c monoclonal antibodies in an indirect im-
munoﬂ  uorescence assay (8). The second method was de-
tection of immunoglobulin M antibodies to DENV by an 
ELISA on serum samples from patients >7 days after onset 
of symptoms (9). The third method was nucleic acid ampli-
ﬁ  cation and typing by a seminested reverse transcription–
PCR (RT-PCR) protocol on the basis of that described by 
Lanciotti et al. (10). 
Brieﬂ  y, viral RNA was extracted by using the QIAamp 
Viral RNA Mini Kit (QIAGEN, Valencia, CA, USA), and 
reverse transcription was conducted on 5 μL of extracted 
RNA with Superscript III (Invitrogen, Carlsbad, CA, USA) 
and random primers. After incubation for 1 h at 50°C, 2 μL 
of each cDNA was subjected to PCR ampliﬁ  cation with D1 
and D2 primers for 35 cycles consisting of 1 min at 94°C, 
1 min at 55°C, and 1 min at 72°C, and a ﬁ  nal extension 
for 10 min at 72°C. A second round of ampliﬁ  cation was 
conducted with 10 μL (diluted 1:100) of the ﬁ  rst amplicon, 
a mixture of type-speciﬁ  c reverse primers (TS1–TS4), and 
the conserved forward primer D1. The same cycling pa-
rameters were used as in the ﬁ  rst reaction.
DENV-4 was detected in 3 samples (AM750, AM1041, 
and AM1619) by virus culture or RT-PCR. It was iden-
tiﬁ   ed as a co-infecting virus with DENV-3 in isolate 
AM750; samples AM1041 and AM1619 represented sin-
gle DENV-4 infections (Table). To conﬁ  rm these results, 
samples were reampliﬁ  ed with each PCR typing primer 
separately. Generated amplicons were cloned into a TA 
vector (Invitrogen), and >3 colonies for each sample were 
sequenced in both directions by using the BigDye Termina-
tor Cycle Sequence Kit (Applied Biosystems, Foster City, 
CA, USA). DENV-3 and DENV-4 nucleotide sequences 
obtained were subjected to a basic local alignment search 
tool (BLAST) (www.ncbi.nlm.nih.gov/) analysis that used 
the megablast algorithm optimized for highly similar se-
quences. Using this approach, we obtained sequences with 
identities ranging from 95% to 99% for DENV-3 and 94% 
to 98% for DENV-4 for isolates AM750-D3, AM750-D4, 
and AM1619. These results conﬁ  rmed our results obtained 
with monoclonal antibodies and PCR typing assays. The 
nucleotide sequences were deposited in GenBank under ac-
cession nos. EU127898 (AM750-D3), EU127899 (AM750-
D4), and EU127900 (AM1619).
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patients who lived and worked in Manaus and reported no 
travel history for >15 days before onset of symptoms. These 
samples were obtained during another study that identiﬁ  ed 
62 DENV-positive samples from January 2005 through 
June 2007 (24 DENV-2, 35 DENV-3, and the 3 DENV-4 
cases in our study) among 128 samples tested from patients 
in 14 municipalities in Amazonas.
Conclusions
Since its introduction into the Western Hemisphere in 
1981, DENV-4 has been associated with dengue fever and 
only sporadically associated with serious cases of DHF or 
DSS (1). A study in Colombia found more DHF patients 
infected with DENV-2 than with DENV-3 or DENV-4 
(11). Conversely, another study showed an association of 
DENV-4 with an epidemic of DHF that occurred in Mexico 
in 1984 (12).
There are many host (and perhaps viral) factors in den-
gue infections that may lead to development of DHF. On the 
basis of the antibody-dependent enhancement hypothesis, 
the most important factors would be those generated by the 
patient’s immune response upon secondary infections (13). 
The 3 isolates reported in our study were from patients with 
no travel history, which indicates that DENV-4 is present 
in Manaus. Detection of DENV-4 in Brazil co-circulating 
with other DENV serotypes endemic to this country rep-
resents an increased risk for DHF or DSS because many 
persons have been sensitized by previous dengue infections 
but are not protected against infection with DENV-4.
The ﬁ  rst report of DENV-4 in Brazil was in the state 
of Roraima in 1982. Since that time, no other isolate of 
DENV-4 has been reported in any part of Brazil (14,15). 
The resurgence of DENV-4 in the Amazon region of Brazil 
most likely resulted from the proximity of Brazil to DENV-
4–endemic countries (Venezuela and Colombia). Addi-
tional genotyping studies are being conducted to verify this 
assumption and to obtain information on dengue epidemi-
ology in Brazil.
Our study documents the detection of DENV-4 in 
Manaus, Amazonas, and the ﬁ  rst isolation of this serotype 
in Brazil in 25 years. These ﬁ  ndings reinforce the need for 
continual epidemiologic studies and use of classic and mo-
lecular approaches in the surveillance of emerging or re-
emerging diseases.
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Table. Results of different methods used to confirm dengue virus type 4 (DENV-4) infection, Manaus, Amazonas, Brazil* 
Virus culture†  M-PCR S-PCR
Isolate
IgM antibody 
capture ELISA  D1 D2 D3 D4 D1 D2 D3 D4 D1 D2 D3 D4 BLAST
AM750 – – – + + – – + + – – + + DENV-3/ DENV-4‡ 
AM1041 + – – – + – – – + – – – + NS
AM1619 + – – – + – – – + – – – + DENV-4
*IgM, immunoglobulin M; M-PCR, multiplex typing PCR described by Lanciotti et al. (10); S-PCR, single serotype-specific primer PCR; D, dengue 
serotype; BLAST, basic local alignment search tool; NS, not sequenced.  
†Viral antigens detected by immunofluorescence with type-specific monoclonal antibodies. 
‡Isolate AM750 is from a person with a co-infection; different clones were sequenced. 
Figure. Location of Amazonas State and Manaus City, Brazil. CO, 
Colombia; VE, Venezuela; RR, State of Roraima.Dengue Virus Type 4, Brazil
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